Loading company…
Tessellate BIO develops precision cancer treatments based on synthetic lethality.
Founded in 2020 and based in Naarden, Netherlands, Tessellate BIO develops cancer treatments using synthetic lethality, with approaches tailored to tumor genotype or phenotype. Its work includes companion diagnostics as part of a precision medicine strategy. In 2023, the company raised EUR 8 million in seed funding from BioGeneration Ventures and Forbion.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in